{"a":[{"_":"AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure","$":{"href":"/pharma/astrazeneca-touts-enhertu-orpathys-dual-lung-cancer-wins-amid-bispecific-failure","hreflang":"en"}}]}
Phase 3MixedEnhertuOrpathysTagrissoNeutral
AI Analysis
Summary
AstraZeneca reported Phase 3 wins for Enhertu and an Orpathys/Tagrisso combination in lung cancer, but a PD-1/CTLA-4 bispecific antibody candidate failed in simultaneous readout.
Clinical Trial Data
Phase
3
Outcome Details
Enhertu and Orpathys/Tagrisso combination showed positive Phase 3 results in lung cancer; PD-1/CTLA-4 bispecific antibody failed
Importance:8/10
Sentiment:
0.10
Phase 3lung cancerclinical trialmixed results
Related Companies
Read the original article
Published by FiercePharma on August 17, 2026 9:55 AM